OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 21, 2020
The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.
January 20, 2020
While the US public and law makers push for price controls, pharma’s venture capitalists have other ideas for balancing innovation and affordability.
A development and manufacturing partnership with Thermo will allow Civica to expand its internal pipeline of medications for use in emergency and critical care in the United States, further preventing the risk of drug shortages.
January 16, 2020
The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.
January 10, 2020
Generic pharmaceutical company, Hikma Pharmaceuticals, and biopharmaceutical company, Arecor, have entered into an exclusive agreement for the development and commercialization of a ready-to-use injectable medicine.
January 09, 2020
Under the agreement, Almirall will leverage WuXi Biologics’ proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.
January 08, 2020
The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.
Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.
January 06, 2020
Molecular taggants from Applied DNA Sciences and Colorcon’s Opadry coating target counterfeit and falsified medications.
January 02, 2020
The promise of new therapies is tempered by the need for affordability, safety, and ethics.